{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:37:06Z","timestamp":1790613426820,"version":"4.1.0"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,12,2]],"date-time":"2020-12-02T00:00:00Z","timestamp":1606867200000},"content-version":"vor","delay-in-days":367,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seizure-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seizure"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.seizure.2019.10.023","type":"journal-article","created":{"date-parts":[[2019,11,5]],"date-time":"2019-11-05T12:23:38Z","timestamp":1572956618000},"page":"75-78","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Efficacy and serum concentrations of perampanel for treatment of drug-resistant epilepsy in children, adolescents, and young adults: comparison of patients younger and older than 12 years"],"prefix":"10.1016","volume":"73","author":[{"given":"Satoru","family":"Ikemoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin-ichiro","family":"Hamano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Hirata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuki","family":"Matsuura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reiko","family":"Koichihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.seizure.2019.10.023_bib0005","doi-asserted-by":"crossref","first-page":"56","DOI":"10.5698\/1535-7511-11.2.56","article-title":"Revisiting AMPA receptors as an antiepileptic drug target","volume":"11","author":"Rogawski","year":"2011","journal-title":"Epilepsy Curr"},{"key":"10.1016\/j.seizure.2019.10.023_bib0010","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1007\/s40263-012-0021-2","article-title":"Perampanel: as adjunctive therapy in patients with partial-onset seizures","volume":"26","author":"Plosker","year":"2012","journal-title":"CNS Drugs"},{"key":"10.1016\/j.seizure.2019.10.023_bib0015","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.eplepsyres.2017.06.002","article-title":"The neuroprotective effect of perampanel in lithium-pilocarpine rat seizure model","volume":"137","author":"Wu","year":"2017","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.seizure.2019.10.023_bib0020","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/j.1528-1167.2010.02522.x","article-title":"Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005-2009","volume":"51","author":"Berg","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2019.10.023_bib0025","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jpba.2014.12.018","article-title":"High-performance liquid chromatography-tandem mass spectrometry method for the detection of perampanel, a novel alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist in human plasma","volume":"107","author":"Mano","year":"2013","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.seizure.2019.10.023_bib0030","author":"French","year":"2014","journal-title":"68th American Epilepsy Society Annual Meeting"},{"key":"10.1016\/j.seizure.2019.10.023_bib0035","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.yebeh.2018.06.033","article-title":"Efficacy and tolerability of perampanel in children and adolescents with pharmacoresistant epilepsy: the first real-world evaluation in Asian pediatric neurology clinics","volume":"85","author":"Lin","year":"2018","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.seizure.2019.10.023_bib0040","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1111\/epi.13894","article-title":"Anti-ictogenic and antiepileptogenic properties of perampanel in mature and immature rats","volume":"58","author":"Dupuis","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2019.10.023_bib0045","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.yebeh.2016.06.041","article-title":"Efficacy and tolerability of perampanel in ten patients with Lafora disease","volume":"62","author":"Goldsmith","year":"2016","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.seizure.2019.10.023_bib0050","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ebcr.2017.05.004","article-title":"Efficacy of perampanel for controlling seizures and improving neurological dysfunction in a patient with dentatorubral-pallidoluysian atrophy (DRPLA)","volume":"8","author":"Shiraishi","year":"2017","journal-title":"Epilepsy Behav Case Rep"},{"key":"10.1016\/j.seizure.2019.10.023_bib0055","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1111\/epi.13662","article-title":"Perampanel in 12 patients with Unverricht-Lundborg disease","volume":"58","author":"Crespel","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2019.10.023_bib0060","doi-asserted-by":"crossref","first-page":"205","DOI":"10.2176\/nmc.ra.2015-0344","article-title":"The new antiepileptic drugs: their neuropharmacology and clinical indications","volume":"56","author":"Hanaya","year":"2016","journal-title":"Neurol Med Chir (Tokyo)"},{"key":"10.1016\/j.seizure.2019.10.023_bib0065","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1055\/s-0035-1546276","article-title":"Effectiveness and tolerability of perampanel in children and adolescents with refractory epilepsies: first experiences","volume":"46","author":"Biro","year":"2015","journal-title":"Neuropediatrics"},{"key":"10.1016\/j.seizure.2019.10.023_bib0070","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/dmcn.13362","article-title":"Tolerability and efficacy of perampanel in children with refractory epilepsy","volume":"59","author":"Heyman","year":"2017","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.seizure.2019.10.023_bib0075","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1212\/WNL.0000000000001558","article-title":"Perampanel efficacy and tolerability with enzyme-inducing AEDs in patients with epilepsy","volume":"84","author":"Gidal","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2019.10.023_bib0080","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1111\/ane.12874","article-title":"Pharmacokinetic\/pharmacodynamic analysis of adjunctive perampanel in subjects with partial-onset seizures","volume":"137","author":"Takenaka","year":"2018","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.seizure.2019.10.023_bib0085","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1097\/FTD.0000000000000416","article-title":"Therapeutic drug monitoring for perampanel in Japanese epilepsy patients: influence of concomitant antiepileptic drugs","volume":"39","author":"Yamamoto","year":"2017","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.seizure.2019.10.023_bib0090","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/FTD.0000000000000274","article-title":"Perampanel serum concentrations in adults with epilepsy: effect of dose, age, sex, and concomitant anti-epileptic drugs","volume":"38","author":"Patsalos","year":"2016","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.seizure.2019.10.023_bib0095","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.eplepsyres.2016.08.001","article-title":"Safety, efficacy and outcome-related factors of perampanel over 12 months in a real-world setting: the FYDATA study","volume":"126","author":"Villanueva","year":"2016","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.seizure.2019.10.023_bib0100","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/epi.12527","article-title":"Perampanel for adjunctive treatment of partial-onset seizures: a pooled dose-response analysis of phase III studies","volume":"55","author":"Kramer","year":"2014","journal-title":"Epilepsia"}],"container-title":["Seizure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131119301360?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131119301360?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T01:53:24Z","timestamp":1761011604000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1059131119301360"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":20,"alternative-id":["S1059131119301360"],"URL":"https:\/\/doi.org\/10.1016\/j.seizure.2019.10.023","relation":{},"ISSN":["1059-1311"],"issn-type":[{"value":"1059-1311","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and serum concentrations of perampanel for treatment of drug-resistant epilepsy in children, adolescents, and young adults: comparison of patients younger and older than 12 years","name":"articletitle","label":"Article Title"},{"value":"Seizure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seizure.2019.10.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 British Epilepsy Association. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}